Hacker News new | ask | show | jobs
by helloworld 3219 days ago
This sounds awesome. How might it complement the "visual paired comparison" task of Zola et al. (2013) -- which has been commercialized by Neurotrack -- in helping to identify those at risk of dementia?

Zola, S.M., Manzanares, C.M, Clopton, P., Lah, J.J., and Levey, A.I. (2013). Am J Alzheimers Dis Other Demen. 28(2): 179–184. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3670591/

1 comments

There are many tests to tell you the risk of developing dementia, which is only a "probability" number. Darmiyan's brain maps show (and measure) the actual pathology (neurodegeneration) in the brain, at microscopic resolution.

There is currently no other method to detect and quantify micro-structural abnormality in the brain at presymptomatic stages of dementia, which is one of the main reasons why all clinical trials of Alzheimer's test drugs keep failing, one after another.